

**Translation**

Notice : This is a translation of the original document in Japanese and is only for reference purposes.  
In the event of any discrepancies between this translated document and the original Japanese document, the latter shall prevail.



August 18, 2025

For Immediate Release

Company name: Mitsubishi Research Institute, Inc.  
Representative: Kenji Yabuta, President  
(Codenumber: 3636; PrimeMarket, TSE)  
Contact: Koichiro Uozumi, Manager,  
Group Corporate Planning Division  
(Email: ir-info@mri.co.jp)

**Notice Concerning Partial Sale of Shares in an Affiliated Company**

Mitsubishi Research Institute, Inc. (MRI) hereby announces the partial sale of the MRI Group's shareholding in Japan Business Systems, Inc. (securities code: 5036, listed on the Standard Market of the Tokyo Stock Exchange; President & CEO: Yukihiro Makita; hereinafter, "JBS") by way of secondary offering as well as the expected recording of extraordinary income due to the sale. Details are as follows.

For details of the secondary offering (hereinafter, the "Secondary Offering") to be conducted by JBS, please refer to the press release issued by JBS today.

**Details**

**1. About the Secondary Offering**

JBS, which is an equity-method affiliate of MRI, decided to conduct a secondary offering of its shares for the purpose of increasing its tradable share ratio in order to seek listing on the Prime Market. MRI judged that the Secondary Offering would help improve the corporate value of JBS, and it has now been decided that, among the 7,011,200 shares of JBS stock held by the MRI Group, Mitsubishi Research Institute DCS Co., Ltd. (hereinafter, "DCS"), which is a consolidated subsidiary of MRI, will sell 1,700,000 shares, which represent a portion of its shareholding.

In addition, MRI and DCS have agreed with the underwriters that they will not sell their remaining shareholdings in JBS during the period beginning on the pricing date for the Secondary Offering and ending on the date that is 180 days from and including the delivery date of the Secondary Offering by way of purchase and underwriting by the underwriter,

which is Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. (hereinafter, "MUMSS"), without the prior written consent of MUMSS, in principle.

## 2. Impact on financial results

In its consolidated financial results for the fiscal year ending September 30, 2025, MRI expects to post a gain on the sale of investment securities of 1.4billion yen (rough estimate calculated based on the closing price of the shares of JBS as of August 8, 2025) in connection with the Secondary Offering under extraordinary income.

The effects of other factors besides the Secondary Offering on MRI's consolidated results for the fiscal year ending September 30, 2025 are also being reviewed. If there is any information that should be disclosed going forward, MRI will make announcements promptly.

Even after the Secondary Offering, JBS will remain an equity-method affiliate of MRI.